Literature DB >> 29435388

Impact of Laboratory Practice Changes on the Diagnosis of Tuberculosis with the Introduction of Xpert MTB/RIF in Kiribati.

Alfred Tonganibeia1,2,3,4, Anthony D Harries1,2,3,4, Onofre Edwin A Merilles1,2,3,4, Tekaibeti Tarataake1,2,3,4, Teatao Tiira1,2,3,4, Takeieta Kienene1,2,3,4.   

Abstract

The Republic of Kiribati, Central Pacific, has the largest tuberculosis epidemic in the region. There is a national tuberculosis control program, which has used smear microscopy for acid-fast bacilli as the main diagnostic tool for many years. In 2015, an Xpert MTB/RIF machine was procured and became functional within the tuberculosis hospital. The aim of this cross-sectional study, using routinely collected data, was to determine the effects of introducing Xpert MTB/RIF on laboratory smear microscopy practices and the pattern of registered tuberculosis cases. Between February 2015 and January 2016, there were 220 Xpert MTB/RIF assays performed with 6.4% errors and 15% detection of Mycobacterium tuberculosis: one patient showed rifampicin-resistance. One year before and after introducing Xpert MTB/RIF, the number of presumptive tuberculosis patients increased by 9% from 2,138 to 2,322. There were no changes in demographic characteristics, smear-positive results, or acid-fast bacilli grade between the two periods. The number of specimens cultured for Mycobacterium tuberculosis significantly declined from 638 to zero, with 76 positive MTB cultures before and none after introducing Xpert MTB/RIF. There was a significant change in the profile of registered tuberculosis cases with more children (34% versus 21%) and fewer bacteriologically-confirmed cases (29% versus 43%) - P < .001. Since the deployment of Xpert MTB/RIF in Kiribati, there have been a small number of assays performed and this has been associated with no adverse effects on smear microscopy, a stoppage in mycobacterial cultures, and a change in the types and categories of diagnosed tuberculosis.

Entities:  

Keywords:  Kiribati; Xpert MTB/RIF; culture for Mycobacterium tuberculosis; smear microscopy services; tuberculosis; types of tuberculosis

Mesh:

Year:  2018        PMID: 29435388      PMCID: PMC5801526     

Source DB:  PubMed          Journal:  Hawaii J Med Public Health        ISSN: 2165-8242


  15 in total

1.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  Bull World Health Organ       Date:  2007-11       Impact factor: 9.408

2.  Diagnosis and treatment of TB patients with rifampicin resistance detected using Xpert(®) MTB/RIF in Zimbabwe.

Authors:  K Charambira; S Ade; A D Harries; R T Ncube; C Zishiri; C Sandy; H Mutunzi; K Takarinda; P Owiti; P Mafaune; P Chonzi
Journal:  Public Health Action       Date:  2016-06-21

3.  Tuberculosis case burden and treatment outcomes in children, adults and older adults, Vanuatu, 2007-2011.

Authors:  M Tagaro; A D Harries; B Kool; S Ram; K Viney; B Marais; L Tarivonda
Journal:  Public Health Action       Date:  2014-06-21

4.  Rapid molecular detection of tuberculosis and rifampin resistance.

Authors:  Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins
Journal:  N Engl J Med       Date:  2010-09-01       Impact factor: 91.245

Review 5.  Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test.

Authors:  Stephen D Lawn; Peter Mwaba; Matthew Bates; Amy Piatek; Heather Alexander; Ben J Marais; Luis E Cuevas; Timothy D McHugh; Lynn Zijenah; Nathan Kapata; Ibrahim Abubakar; Ruth McNerney; Michael Hoelscher; Ziad A Memish; Giovanni Battista Migliori; Peter Kim; Markus Maeurer; Marco Schito; Alimuddin Zumla
Journal:  Lancet Infect Dis       Date:  2013-03-24       Impact factor: 25.071

Review 6.  Diagnosis of pulmonary tuberculosis.

Authors:  Stephen D Lawn
Journal:  Curr Opin Pulm Med       Date:  2013-05       Impact factor: 3.155

7.  Evaluation of the implementation of the Xpert® MTB/RIF assay in Fiji.

Authors:  A Gounder; S Gounder; S A Reid
Journal:  Public Health Action       Date:  2014-09-21

8.  Characteristics and programme-defined treatment outcomes among childhood tuberculosis (TB) patients under the national TB programme in Delhi.

Authors:  Srinath Satyanarayana; Roopa Shivashankar; Ram Pal Vashist; Lakhbir Singh Chauhan; Sarabjit Singh Chadha; Puneet Kumar Dewan; Fraser Wares; Suvanand Sahu; Varinder Singh; Nevin Charles Wilson; Anthony David Harries
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

9.  Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries.

Authors:  Jacob Creswell; Andrew J Codlin; Emmanuel Andre; Mark A Micek; Ahmed Bedru; E Jane Carter; Rajendra-Prasad Yadav; Andrei Mosneaga; Bishwa Rai; Sayera Banu; Miranda Brouwer; Lucie Blok; Suvanand Sahu; Lucica Ditiu
Journal:  BMC Infect Dis       Date:  2014-01-02       Impact factor: 3.090

10.  The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement.

Authors:  Eric I Benchimol; Liam Smeeth; Astrid Guttmann; Katie Harron; David Moher; Irene Petersen; Henrik T Sørensen; Erik von Elm; Sinéad M Langan
Journal:  PLoS Med       Date:  2015-10-06       Impact factor: 11.069

View more
  3 in total

1.  Has the utilisation of Xpert® MTB/RIF in Manicaland Province, Zimbabwe, improved with new guidance on whom to test?

Authors:  A Jokwiro; C Timire; A D Harries; P T Gwinji; A Mulema; K C Takarinda; P T Mafaune; C Sandy
Journal:  Public Health Action       Date:  2018-09-21

2.  Scaling Up Molecular Diagnostic Tests for Drug-Resistant Tuberculosis in Uzbekistan from 2012-2019: Are We on the Right Track?

Authors:  Sharofiddin Yuldashev; Nargiza Parpieva; Salikhdjan Alimov; Laziz Turaev; Khasan Safaev; Kostyantyn Dumchev; Jamshid Gadoev; Oleksandr Korotych; Anthony D Harries
Journal:  Int J Environ Res Public Health       Date:  2021-04-28       Impact factor: 3.390

Review 3.  What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030?

Authors:  Anthony D Harries; Yan Lin; Ajay M V Kumar; Srinath Satyanarayana; Kudakwashe C Takarinda; Riitta A Dlodlo; Rony Zachariah; Piero Olliaro
Journal:  F1000Res       Date:  2018-07-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.